BioSpace News Archive

Isofol Medical AB, announced that a notice that a Clinical Use Patent for the drug candidate arfolitixorin will be approved in Europe.

Raybow USA Inc, the North American unit of a global provider of outsourced pharmaceutical process development and manufacturing services, will expand its operations in North Carolina, tripling both its capacity and workforce.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that Chairperson and Chief Executive Officer, Tony Coles, M.D. will participate in a fireside chat at the Stifel 3rd Annual CNS Day on Wednesday, March 31, 2021 at 9:00 a.m. EDT.

Most people with cancer who are infected by the novel coronavirus produce antibodies at a rate comparable to the rest of the population—but their ability to do so depends on their type of cancer and the treatments they’ve received, according to a new study by researchers at Montefiore Health System and Albert Einstein College of Medicine.

Innoforce Pharmaceuticals, a biopharmaceutical innovation and partnership company, announced the completion of a 625M CNY Series A financing, which follows a 170M CNY Pre-A financing completed in June 2020.

FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies

Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated

The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, provided details of four presentations that were made at the Endocrine Society’s annual ENDO 2021 congress on the company’s product pipeline.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Executive Vice President, Chief Operating Officer (COO) and principal executive officer at Abeona, has been promoted to President, Chief Executive Officer (CEO) and a member of the company’s Board of Directors, effective immediately.